Abstract 1408P
Background
PDT using the novel photosensitizer DVDMS has shown promising activity in treating esophageal stenosis and improving dysphagia in local recurrent or metastatic EC in phase II study previously, with an esophageal stenosis overall response rate (es-ORR) of 40% at day 28 under a 102 J/cm light dose at 24-hour intervals. This phase IIIb trial aims to further assess the efficacy and safety of DVDMS-mediated PDT.
Methods
This trial enrolled patients with previously treated advanced EC, with a Stooler dysphagia grade ≥ 2 (CTR20221271). Patients were randomized 2:1 to receive DVDMS-mediated PDT (DVDMS of 0.2 mg/kg, light dose of 102 J/cm, PDT delivered at 630±5 nm 24±2 hours intervals) or treatment of physician’s choice, including chemotherapy and best supportive care. The primary endpoint was es-ORR.
Results
As of December 31, 2023, 84 eligible pts had completed the day 28 follow-up or censored. At day 28, the DVDMS-PDT group (n=56) exhibited an es-ORR of 48.21% (95% CI: 34.66-61.97), significantly higher than the control group's 3.57% (95% CI: 0.09-18.35, P < 0.0001). Average esophageal diameter increases were 1.76 mm and -0.67 mm. Other endpoints are detailed in the table. Treatment-emergent adverse events occurred in 80.36% of the DVDMS-PDT group and 92.86% of controls. Phototoxicity was negative in 75% patients in DVDMS-PDT group on day 7, increasing to 94.64% by day 28. Two deaths related to adverse events in the DVDMS-PDT group (one possibly treatment-related) and four in the control group.
Conclusions
Preliminary results indicates that DVDMS-mediated PDT has significant higher es-ORR and improves dysphagia as well as quality of life with a favorable safety profile compared with treatment of physician’s choice, emphasizes this new option for advanced EC with dysphagia. The trial is ongoing. Table: 1408P
| Outcomes on day 28 | DVDMS PDT (n=56) | Treatment of physician’s choice (n=28) |
| Reduction at least 1 grade in Stooler's dysphagia grade, n (%) | 18 (32.14) | 0 |
| Mean change from baseline in Stooler's dysphagia score | -0.4 | 0.1 |
| Mean change from baseline in EORTC QLQ-C30 overall health score (Higher scores indicate better overall health) | 3.442 | -1.471 |
| Mean change from baseline in EORTC QLQ-OES18 dysphagia score (Higher scores indicate more severe symptoms) | -3.140 | 0.000 |
| Mean change from baseline in EORTC QLQ-OES18 eating score (Higher scores indicate more severe symptoms) | -10.145 | -3.431 |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Guangsheng Pharmaceutical Co., Ltd.
Funding
Shanghai Guangsheng Pharmaceutical Co., Ltd.
Disclosure
S. Zhang: Financial Interests, Personal and Institutional, Affiliate: Shanghai Guangsheng Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
983P - Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study
Presenter: Xiao-Ping Chen
Session: Poster session 17
984P - Regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: Interim results from the multicenter real-world study
Presenter: Jian Lu
Session: Poster session 17
Resources:
Abstract
985P - Analysis of antidrug antibodies (ADA) to camrelizumab in CARES-310: The pivotal phase III study of camrelizumab + rivoceranib in unresectable hepatocellular carcinoma (uHCC)
Presenter: Ahmed Kaseb
Session: Poster session 17
987TiP - First-in-human dose escalation trial of fourth generation chimeric antigen receptor (CAR) T cell therapy (EU307) in patients with glypican-3 (GPC3) positive hepatocellular carcinoma (HCC)
Presenter: Do-Young Kim
Session: Poster session 17
1150P - Search for biomarkers to personalize treatment with streptozotocin plus 5-fluorouracil or everolimus in patients with advanced pancreatic neuroendocrine tumors: The randomized phase III SEQTOR trial (GETNE-1206)
Presenter: Ramon Salazar Soler
Session: Poster session 17
1151P - Biochemical and radiological efficacy of systmic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma/pheochromocytoma (PPGL) sporadic and hereditary
Presenter: Agnieszka Kolasińska-Ćwikła
Session: Poster session 17
1152P - Correlation of biochemical secretion and imaging parameters on [18F]-SiTATE-PET/CT in pheochromocytoma and paraganglioma
Presenter: Meike Onkes
Session: Poster session 17
1153P - Preclinical characterization of MC339: A novel radiotherapeutic agent for DLL3 expressing cancers
Presenter: Anneli Savinainen
Session: Poster session 17